Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 1450 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:


1.		PETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Treatment				Completed				15 and over				Other				LAL-RI/96 NCT00494897

Last Modified: 11/1/1997


2.		Phase II/III Pilot Treatment of Pediatric Non-B, Non-T ALL in First Marrow Relapse (SIMAL #8): Intensive Re-Induction and Reconsolidation Chemotherapy with Subsequent Myeloablative Chemoradiotherapy and Rescue with Either Allogeneic or In Vitro-Purged Autologous Marrow (Summary Last Modified 11/97)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Completed				under 21 at relapse				NCI				POG-9410 POG-SIMAL-8

Last Modified: 11/13/2008 First Published: 8/1/1998


3.		Phase II Study of Observation in Patients With Favorable Low-Grade Glioma and a Phase III Study of Radiotherapy With or Without Procarbazine, Lomustine, and Vincristine in Patients With Unfavorable Low-Grade Glioma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				18 and over				NCI				RTOG-9802 E-R9802, NCCTG-R9802, SWOG-R9802, RTOG-DEV-1012, NCT00003375, RTOG-98-02


4.		Phase II-III Chemotherapy with BLEO/DTIC/VBL/ADR/PRED or NM/VCR/PCB/PRED Plus Radiotherapy for Advanced Hodgkin's Disease

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				no age specified								DFCI-75100


5.		Phase II-III VCR/PRED/L-ASP Induction, CNS Therapy plus MTX vs 6-MP/MTX vs 6-MP/MTX/CTX vs 6-MP/MTX/CTX/ARA-C for Pediatric ALL

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				under 18								SJCRH-ALL-TT-8

Last Modified: 7/6/2007


6.		Phase II-III FAM (5-FU/ADR/MITO) vs V-FAM (FAM/VCR) vs Phase II Agent Chemotherapy for Advanced Gastric Adenocarcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Completed				no age specified				NCI				SWOG-7841


7.		Phase II/III Chemotherapy and Hormone Therapy with ADR/VCR/DBD/PRED Followed by TMX/FXM/BLEO/HMM/MTX-CF for Metastatic Stage III/IV or Recurrent Breast Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				under 65								WCCC-CO-7711R NCI-D80-048-183


8.		Phase II/III Timed Sequential Chemotherapy with CTX and VCR for Refractory or High-Risk Myeloma (Summary last modified 06/97)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Completed				no age specified				NCI				EST-4480


9.		Phase II-III Chemotherapy with High-Dose Methotrexate and Adriamycin plus Radiotherapy for Primary and Metastatic Osteogenic Sarcoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				20 and under								CHOP-204


10.		Phase II Chemotherapy with MTX/CF, Aminopterin or M-BACOD plus CTX or BCG Immunotherapy for Advanced non-Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				25 to 65								DFCI-75116

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute